Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Trial ID or NCT#
The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of VOD through the analysis of blood samples.
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy
- - Clinical diagnosis of VOD, defined by jaundice (bilirubin >/= 2 mg/dL) and at least 2 of the following clinical findings, by Day+21 post stem cell transplant: ascites; weight gain >/= 5% above baseline weight; hepatomegaly. - Severe VOD, defined as VOD with multi-organ failure, i.e., presence of one or both of the following, by Day+28 post stem cell transplant: renal or pulmonary dysfunction. - Provide voluntary written informed consent.
- - Pre-existing (prior to SCT) cirrhosis - An alternative diagnosis for weight gain, ascites and jaundice - Graft-versus-host disease (GVHD) grade B or higher involving liver or gut or grade C or higher involving skin - Prior solid organ transplant - Dependent on dialysis prior to and/or at the time of SCT - Dependent on oxygen supplementation prior to SCT - Significant acute bleeding or hemodynamic instability - Requirement for the use of any medications that increase risk of hemorrhage will be excluded from the treatment group
Contact us to find out if this trial is right for you.